Immunitybio announces european medicines agency acceptance of marketing authorization application for anktiva® for the treatment of patients with bcg-unresponsive non-muscle invasive bladder cancer carcinoma in situ

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced the european medicines agency (ema) has accepted for review and begun assessing the marketing authorization application (maa) for anktiva (nogapendekin alfa inbakicept-pmln) in combination with bacillus calmette-guÉrin (bcg) for the treatment of patients with bcg-unresponsive non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), with or without papillary tu.
IBRX Ratings Summary
IBRX Quant Ranking